Manhattan Institute

Manhattan BioSolutions is a privately held biotechnology company based in New York City, focused on developing a new generation of immunotherapies for the treatment of advanced solid tumors. The company's portfolio leverages three innovative technology platforms: genetically engineered microbial therapies, antibody-drug conjugates (ADCs), and RNA-based therapeutics. Their lead program, MBS-2, is an oncolytic bacterial therapy designed to stimulate a potent anti-tumor immune response. Manhattan BioSolutions aims to address the limitations of current immunotherapies by targeting the tumor microenvironment through multiple synergistic modalities. The company was founded by experienced industry veterans and maintains collaborations with leading academic institutions to advance its diverse pipeline of precision oncology candidates.